Dayvigo

Dayvigo Adverse Reactions

lemborexant

Manufacturer:

Eisai

Concise Prescribing Info Bahasa Concise Prescribing Info Full Prescribing Info Contents Description Action Indications/Uses Dosage/Direction for Use Overdosage Contraindications Special Precautions Use In Pregnancy & Lactation Adverse Reactions Drug Interactions Storage MIMS Class ATC Classification Regulatory Classification Presentation/Packing

Full Prescribing Info

Adverse Reactions

Adverse reactions were reported in 249 (28.2%) of the 884 patients (including 155 Japanese patients) who received lemborexant in an international phase III study involving patients with insomnia.
Major adverse reactions included somnolence in 95 patients (10.7%), headache in 37 patients (4.2%), and malaise in 27 patients (3.1%) (as of the time of approval). (See Table 6.)

Click on icon to see table/diagram/image

View ADR Monitoring Form

Asia's one-stop resource for medical news, clinical reference and education

Already a member? Sign in

Asia's one-stop resource for medical news, clinical reference and education

Already a member? Sign in